Caribou Biosciences’ 2025 outlook aimed for key trial readouts for two cancer cell therapies in the first half of the year and the start of clinical testing in an autoimmune disease. The CRISPR ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending a CRISPR gene editing-based treatment for severe sickle cell disease (SCD). The regulator said ...
CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...
On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with ...
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their ...
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
Victoria Gray, the first person cured of sickle cell using CRISPR gene editing therapies, spoke in Fargo about her journey and the need to lower the $2M treatment cost. Victoria Gray, cured of sickle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback